多重耐药
细胞凋亡
癌细胞
半胱氨酸蛋白酶
生物
癌症研究
化疗
抗药性
程序性细胞死亡
DNA断裂
药理学
癌症
生物化学
微生物学
遗传学
出处
期刊:Leukemia
[Springer Nature]
日期:2001-06-01
卷期号:15 (6): 936-941
被引量:87
标识
DOI:10.1038/sj.leu.2402127
摘要
Many chemotherapeutic agents induce apoptosis in tumor cells, but killing of normal cells remains a major obstacle. Development of multidrug resistance further limits chemotherapy in cancer. Here, I show that multidrug resistance can be exploited for selective killing of multidrug-resistant cells by a combination of an apoptosis-inducing agent that is not a substrate of either Pgp or MRP (e.g. flavopiridol) with a caspase inhibitor that is a substrate (e.g. Z-DEVD-fmk). In normal cells, treatment with caspase inhibitors prevented PARP cleavage, nuclear fragmentation, and cell death caused by flavopiridol or epothilone B. In contrast, Pgp- and MRP-expressing cells were not rescued by caspase inhibitors. Furthermore, reversal of drug resistance renders Pgp cells sensitive to caspase inhibitors abolishing therapeutic advantage. Thus, caspase inhibitors, that are inactive in multidrug-resistant cells, protect normal but not multidrug-resistant cells against chemotherapy, permitting selective eradication of multidrug-resistant cells. Clinical application of this approach may diminish the toxic side-effects of chemotherapy in patients with multidrug-resistant tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI